Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 129

Results For "Inc"

6060 News Found

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
People | November 21, 2024

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer


European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors
Drug Approval | November 21, 2024

European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors

HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors


Indegene announces new Center in Hyderabad
Digitisation | November 20, 2024

Indegene announces new Center in Hyderabad

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies


Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


CPHI India reports surge in exhibitor numbers
News | November 20, 2024

CPHI India reports surge in exhibitor numbers

Modernization and supply chain diversity drive new growth


Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Drug Approval | November 19, 2024

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years


Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
Clinical Trials | November 19, 2024

Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex


Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness
Healthcare | November 17, 2024

Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness

Emcure and Dhoni, through a video, urge everyone to be aware about symptoms of stroke and educate at least one person for identification of stroke and spread its awareness